Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988230 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL12949521 | 0.88 | ALDH1A1 (0.35) | ALDH1A1CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL987824 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL987821 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL12923939 | 0.83 | CYP3A4 (0.40) | ALDH1A1KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL8987655 | 0.70 | ALDH1A1 (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL988222 | 0.69 | CYP2D6 (0.35) | ALDH1A1KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL988223 | 0.69 | CYP2D6 (0.35) | ALDH1A1KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL12923940 | 0.68 | ALDH1A1 (0.35) | ALDH1A1KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL12949388 | 0.68 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003776-A1 | TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003776-A1 | TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF | TPMT, TYMS, QDPR | ALDH1A1 1282/4885KDM4E 2763/4885KCNH2 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.